265 related articles for article (PubMed ID: 25726356)
1. Reprint of: The prostate cancer genome: Perspectives and potential.
Barbieri CE; Tomlins SA
Urol Oncol; 2015 Feb; 33(2):95-102. PubMed ID: 25726356
[TBL] [Abstract][Full Text] [Related]
2. The prostate cancer genome: perspectives and potential.
Barbieri CE; Tomlins SA
Urol Oncol; 2014 Jan; 32(1):53.e15-22. PubMed ID: 24239470
[TBL] [Abstract][Full Text] [Related]
3. The mutational landscape of prostate cancer.
Barbieri CE; Bangma CH; Bjartell A; Catto JW; Culig Z; Grönberg H; Luo J; Visakorpi T; Rubin MA
Eur Urol; 2013 Oct; 64(4):567-76. PubMed ID: 23759327
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer genomics by high-throughput technologies: genome-wide association study and sequencing analysis.
Nakagawa H
Endocr Relat Cancer; 2013 Aug; 20(4):R171-81. PubMed ID: 23625613
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity.
Barbieri CE; Demichelis F; Rubin MA
Histopathology; 2012 Jan; 60(1):187-98. PubMed ID: 22212086
[TBL] [Abstract][Full Text] [Related]
6. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
8. Sequencing the transcriptional network of androgen receptor in prostate cancer.
Chng KR; Cheung E
Cancer Lett; 2013 Nov; 340(2):254-60. PubMed ID: 23196061
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology of prostate-cancer pathogenesis.
Shand RL; Gelmann EP
Curr Opin Urol; 2006 May; 16(3):123-31. PubMed ID: 16679847
[TBL] [Abstract][Full Text] [Related]
10. ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA; Bjartell A; Chinnaiyan AM; Jenster G; Nam RK; Rubin MA; Schalken JA
Eur Urol; 2009 Aug; 56(2):275-86. PubMed ID: 19409690
[TBL] [Abstract][Full Text] [Related]
11. Genomic approaches to outcome prediction in prostate cancer.
Febbo PG
Cancer; 2009 Jul; 115(13 Suppl):3046-57. PubMed ID: 19544546
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
13. Environmental, genetic, and molecular features of prostate cancer.
Deutsch E; Maggiorella L; Eschwege P; Bourhis J; Soria JC; Abdulkarim B
Lancet Oncol; 2004 May; 5(5):303-13. PubMed ID: 15120667
[TBL] [Abstract][Full Text] [Related]
14. Molecular Updates in Prostate Cancer.
Netto GJ
Surg Pathol Clin; 2015 Dec; 8(4):561-80. PubMed ID: 26612215
[TBL] [Abstract][Full Text] [Related]
15. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
16. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.
Armstrong AJ; Li X; Tucker M; Li S; Mu XJ; Eng KW; Sboner A; Rubin M; Gerstein M
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):786-793. PubMed ID: 33568750
[TBL] [Abstract][Full Text] [Related]
17. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract][Full Text] [Related]
18. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
19. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine for prostate cancer.
Galazi M; Rodriguez-Vida A; Ng T; Mason M; Chowdhury S
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1305-15. PubMed ID: 25354871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
